Vaccine News and Research

Latest Vaccine News and Research

New study reinforces urgent need for life-saving vaccines in Africa

A new study released this week in The Lancet Infectious Diseases finds that African children who contract pneumococcus - a bacterial infection that causes pneumonia, meningitis and sepsis - are 36 times as likely to have sickle-cell disease, a blood disorder prevalent in African children that increases the risk for infectious diseases and early death.

29 Apr 2010

Seasonal flu shots: Are they responsible for the adverse reactions? Investigations on

After the seasonal flu vaccines caused over 250 cases of fever, vomiting and convulsions and one reported death in under-fives there has been intense investigations to detect the cause. Further vaccinations were stopped last Friday.

28 Apr 2010

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Takeda Pharmaceutical Company Limited announced today that Takeda and its wholly owned subsidiary, Takeda Pharmaceuticals North America, Inc., have completed settlement agreements with six out of eight defendants in patent infringement litigation brought against these parties in response to their Abbreviated New Drug Applications for generic ACTOS® (pioglitazone HCl) and ACTOplus met® (pioglitazone HCl and metformin HCl). Takeda recently concluded litigation with the sixth settling defendant.

28 Apr 2010

Study evaluates cost benefits of new interventions for treating, preventing PDN and PHN

Constantly rising U.S. health care costs could be reduced significantly by preventing and treating neuropathic pain conditions associated with diabetes and herpes zoster virus infections, according to research published in The Journal of Pain, the peer review publication of the American Pain Society, www.ampainsoc.org and jpain.org.

28 Apr 2010

BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine

BiondVax Pharmaceuticals Ltd., an Israeli biopharmaceutical company at the forefront of global efforts towards the development of a Universal Influenza Vaccine, announced the successful conclusion of the Company's second Phase I/II clinical trial of the Multimeric-001 Universal Influenza Vaccine.

28 Apr 2010

Pepscan reaches partnering agreement for therapeutic vaccine portfolio with Immunovo

Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.

28 Apr 2010

Researchers develop new diagnostic approach to fight against Chagas disease

Chagas disease is one of the most deadly parasitic diseases in the world. It affects more than 10 million people, primarily in the Americas. In South America alone it kills 50 000 people each year. A reliable and rapid diagnosis is the key in the battle against infection but until now, this has been next to impossible.

28 Apr 2010

Diamyd Medical reports group net sales of MSEK 0.2 for second-quarter 2010

Second quarter report for Diamyd Medical AB (publ), fiscal year 2009/2010

28 Apr 2010

ChronSeal multi-center study in Sweden and Norway finalized

The multi-center study in Sweden and Norway with ChronSeal® is now finalized and the data are being analyzed in Sweden and by Kringle in Japan. ChronTech and Kringle have jointly decided that the results will be publicly available on May 27th. At follow-up of the ChronVac-C® -study where patients now have started treatment according to standard-of-care (interferon and ribavirin) all patients (100%) were virus free at treatment week 12 and 5/6 (83%) had less than 50 copies of virus/mL blood already at treatment week four.

28 Apr 2010

China lifts ban on tourists suffering from HIV/AIDS

In a new development China has lifted its decades old reservations towards travelers and tourists suffering from HIV and AIDS in the wake of the Shanghai World Expo this weekend.

28 Apr 2010

Study results from US Military Malaria Vaccine Program announced

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that the US Military Malaria Vaccine Program presented results of its study using the Biojector2000 with a recombinant DNA vaccine at two recent conferences. A Cooperative Research and Development Agreement was signed with the Navy in April 2009 to work together on the study.

28 Apr 2010

News outlets continue malaria coverage

World Malaria Day was Sunday and news organizations continued to cover local events.

28 Apr 2010

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Generex Biotechnology Corporation today announced presentation of additional results from a recently completed Phase I clinical trial of its novel immunotherapeutic peptide AE37 in prostate cancer patients. AE37 is a synthetic cancer vaccine being developed by Antigen Express, Inc., a wholly owned subsidiary of Generex, for multiple cancer indications.

28 Apr 2010

Australian Medical Association says doctor followed all procedures in flu shot death

The death of a two year old girl a day after she relieved a flu shot has become an issue for the Brisbane doctor who gave the girl and her twin sister the flu shot. The Australian Medical Association branch in Queenland has warned against making Dr Amir Eskandari the scapegoat in the case.

27 Apr 2010

Prime-boost malaria vaccine regimen provides sterile protection: Vical

Vical Incorporated announced today that a prime-boost malaria vaccine regimen provided sterile protection, with no disease symptoms and no detectable malaria parasites, in 4 of 15 vaccinated volunteers a full 28 days after challenge with multiple infected-mosquito bites.

27 Apr 2010

People infected with gastrointestinal worms respond better to injected vaccines

According to the World Health Organization, two billion people around the globe suffer from chronic parasitic worm infections, which, in addition to causing illness and developmental delay, are also suspected to interfere with the effectiveness of ordinary vaccines, making their victims more vulnerable to life-threatening diseases. A recent discovery by researchers at the Trudeau Institute promises to bypass these obstacles and help deliver more effective vaccines to these people, boosting their protection against common childhood diseases.

27 Apr 2010

Vaccine News and Research

Latest Vaccine News and Research

New study reinforces urgent need for life-saving vaccines in Africa

Seasonal flu shots: Are they responsible for the adverse reactions? Investigations on

Takeda settles with six defendants in generic ACTOS, ACTOplus met patent infringement lawsuit

Study evaluates cost benefits of new interventions for treating, preventing PDN and PHN

BiondVax announces successful conclusion of second Phase I/II trial of Multimeric-001 Universal Flu Vaccine

Pepscan reaches partnering agreement for therapeutic vaccine portfolio with Immunovo

Researchers develop new diagnostic approach to fight against Chagas disease

Diamyd Medical reports group net sales of MSEK 0.2 for second-quarter 2010

ChronSeal multi-center study in Sweden and Norway finalized

China lifts ban on tourists suffering from HIV/AIDS

Study results from US Military Malaria Vaccine Program announced

News outlets continue malaria coverage

Phase I clinical trial results of AE37 in prostate cancer patients presented at EAU Congress

Australian Medical Association says doctor followed all procedures in flu shot death

Prime-boost malaria vaccine regimen provides sterile protection: Vical

People infected with gastrointestinal worms respond better to injected vaccines

ASPO meeting to focus on children's ear, nose and throat health

WHO experts to examine polio outbreak in Tajikistan

News outlets examine World Malaria Day 2010

PPD reports 30% sequential increase in gross authorizations for first-quarter 2010

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Vaccine News and Research

Latest Vaccine News and Research

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in